Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia-Reference-Cited by-同舟云学术

Cost Utility of Lifelong Immunoglobulin Replacement Therapy vs Hematopoietic Stem Cell Transplant to Treat Agammaglobulinemia

Author:

Sun Di¹,Heimall Jennifer R.¹²,Greenhawt Matthew J.³⁴,Bunin Nancy J.²⁵,Shaker Marcus S.⁶,Romberg Neil¹²⁷

Affiliation:

1. Department of Pediatrics, Division of Allergy and Immunology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

2. Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia

3. Children's Hospital Colorado, Section of Allergy and Immunology, Food Challenge and Research Unit, Aurora

4. Department of Pediatrics, University of Colorado School of Medicine, Aurora

5. Department of Pediatrics, Division of Oncology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

6. Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Lebanon, New Hampshire

7. Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia

Publisher

American Medical Association (AMA)

Subject

Pediatrics, Perinatology and Child Health

Link

Reference68 articles.

1. Primary antibody deficiencies.;Durandy;Nat Rev Immunol,2013

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献